Phaseline

Targets › TOPOH1

TOPOH1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.

Open in Phaseline: the race on TOPOH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer CenterNALIRIFOX
Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil, leucovori
TOPOH1Phase 2Pancreatic Ductal AdenocarcinomaSep 2027

Conditions

Pancreatic Ductal Adenocarcinoma (1)

Modalities

small molecule (1)

Companies

Memorial Sloan Kettering Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.